Jl. u may have me on ignore ...BUT I agree with your post . AMRN did the hard work and spend the $ to prove the benefit of high dose 96% pure EPA .... and that will save thousands if not millions from heart attacks and strokes
Jesse. The patents ruled as obvious had nothing or little to do with cardiovascular disease. They where about ldl reduction in PEOPLE with trigs over 500. Specifically in regards to aPO B. No REDUCIT talk unless it somehow helps us block the generics.
Doc JL... I think you have me on ignore. So, others can hear me out. The life saving factor of Vascepa ( new indication) must be taken into consideration. My questions is this: did the judge allow anything pertaining to Reduce-it into the trial?
Everyone on the planet knows that any generic approved will infringe on this new patent. How or why should this be overlooked? Do we all realize what this does to future innovation?
I agree with the good doctor. Some how and some way, this indication must be protected.